Phase 1 Study of Vorinostat as a Radiation Sensitizer with (131)I-Metaiodobenzylguanidine ((131)I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma

PURPOSE: (131)I-metaiodobenzylguanidine (MIBG) is a radiopharmaceutical with activity in neuroblastoma. Vorinostat is a histone deacetylase inhibitor that has radiosensitizing properties. The goal of this phase 1 study was to determine the maximum tolerated doses of vorinostat and MIBG in combinatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: DuBois, Steven G., Groshen, Susan, Park, Julie R., Haas-Kogan, Daphne A., Yang, Xiaodong, Geier, Ethan, Chen, Eugene, Giacomini, Kathy, Weiss, Brian, Cohn, Susan L., Granger, M. Meaghan, Yanik, Gregory A., Hawkins, Randall, Courtier, Jesse, Jackson, Hollie, Goodarzian, Fariba, Shimada, Hiroyuki, Czarnecki, Scarlett, Tsao-Wei, Denice, Villablanca, Judith G., Marachelian, Araz, Matthay, Katherine K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4470833/
https://ncbi.nlm.nih.gov/pubmed/25695691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-3240
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados